U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6H8O7
Molecular Weight 192.1235
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ANHYDROUS CITRIC ACID

SMILES

OC(=O)CC(O)(CC(O)=O)C(O)=O

InChI

InChIKey=KRKNYBCHXYNGOX-UHFFFAOYSA-N
InChI=1S/C6H8O7/c7-3(8)1-6(13,5(11)12)2-4(9)10/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)

HIDE SMILES / InChI

Molecular Formula C6H8O7
Molecular Weight 192.1235
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.adm.com/en-US/worldwide/australia/Documents/Potassium%20Citrate%20AU.pdf | https://noshly.com/additive/e332/acidity-regulator-plus/332/#.WUp-1uvyjIU

Potassium citrate is indicated for the management of renal tubular acidosis with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, uric acid lithiasis with or without calcium stones. WhenPotassium citrate is given orally, the metabolism of absorbed citrate produces an alkaline load. The induced alkaline load in turn increases urinary pH and raises urinary citrate by augmenting citrate clearance without measurably altering ultrafilterable serum citrate. Thus, potassium citrate therapy appears to increase urinary citrate principally by modifying the renal handling of citrate, rather than by increasing the filtered load of citrate. Potassium citrate is used as a food additive (E 332) to regulate acidity.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
UROCIT-K

Approved Use

Urocit®-K is a citrate salt of potassium indicated for the management of: • Renal tubular acidosis (RTA) with calcium stones • Hypocitraturic calcium oxalate nephrolithiasis of any etiology • Uric acid lithiasis with or without calcium stones

Launch Date

4.94121615E11
Primary
UROCIT-K

Approved Use

Urocit®-K is a citrate salt of potassium indicated for the management of: • Renal tubular acidosis (RTA) with calcium stones • Hypocitraturic calcium oxalate nephrolithiasis of any etiology • Uric acid lithiasis with or without calcium stones

Launch Date

4.94121615E11
Doses

Doses

DosePopulationAdverse events​
540 mg 1 times / day multiple, oral
Recommended
Dose: 540 mg, 1 times / day
Route: oral
Route: multiple
Dose: 540 mg, 1 times / day
Co-administed with::
Thiamin oral 1.1 mg
Arginine oral 1240 mg
caffeine oral 52 mg
Sources: Page: p.2326
healthy, 24-59
n = 16
Health Status: healthy
Age Group: 24-59
Sex: M+F
Population Size: 16
Sources: Page: p.2326
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Comparative efficacy of "specific" potassium citrate therapy versus conservative management in nephrolithiasis of mild to moderate severity.
1985 Oct
Renal hypouricemia due to enhanced tubular secretion of urate associated with urolithiasis: successful treatment of urolithiasis by alkalization of urine K+, Na(+)-citrate.
1993
[Therapeutic use of potassium citrate].
2001
Evaluation of aggregating brain cell cultures for the detection of acute organ-specific toxicity.
2013 Jun
Patents

Sample Use Guides

In Vivo Use Guide
Objective: To restore normal urinary citrate (greater than 320 mg/day and as close to the normal mean of 640 mg/day as possible), and to increase urinary pH to a level of 6.0 to 7.0. • Severe hypocitraturia (urinary citrate < 150 mg/day): therapy should be initiated at 60 mEq per day; a dose of 30 mEq two times per day or 20 mEq three times per day with meals or within 30 minutes after meals or bedtime snack • Mild to moderate hypocitraturia (urinary citrate >150 mg/day): therapy should be initiated at 30 mEq per day; a dose of 15 mEq two times per day or 10 mEq three times per day with meals or within 30 minutes after meals or bedtime snack
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:01:37 UTC 2023
Edited
by admin
on Fri Dec 15 16:01:37 UTC 2023
Record UNII
XF417D3PSL
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ANHYDROUS CITRIC ACID
II   MART.  
Common Name English
CITRIC ACID (CONSTITUENT OF CRANBERRY LIQUID PREPARATION) [DSC]
Common Name English
FEMA NO. 2306
Code English
CITRIC ACID (CONSTITUENT OF GARCINIA CAMBOGIA AND GARCINIA INDICA) [DSC]
Common Name English
ANHYDROUS CITRIC ACID [MART.]
Common Name English
CITRIC ACID MONOGLYCERIDE
Common Name English
Citric acid [WHO-DD]
Common Name English
ANHYDROUS CITRIC ACID [JAN]
Common Name English
2-HYDROXY-1,2,3-PROPANETRICARBOXYIC ACID
Systematic Name English
ANHYDROUS CITRIC ACID [USP MONOGRAPH]
Common Name English
ACIDUM CITRICUM [WHO-IP LATIN]
Common Name English
CITRIC ACID,ANHYDROUS
VANDF  
Common Name English
CITRIC ACID, ANHYDROUS
EP   USP   WHO-IP  
Common Name English
CITRIC ACID ANHYDROUS
JAN  
Common Name English
CLENPIQ COMPONENT ANHYDROUS CITRIC ACID
Brand Name English
ACILETTEN
Common Name English
1,2,3-PROPANETRICARBOXYLIC ACID, 2-HYDROXY-
Common Name English
ANHYDROUS CITRIC ACID [II]
Common Name English
CITRIC ACID, ANHYDROUS [EP IMPURITY]
Common Name English
NSC-112226
Code English
NSC-626579
Code English
3-CARBOXY-3-HYDROXYPENTANE-1,5-DIOIC ACID
Systematic Name English
CITRICUM ACIDUM
HPUS  
Common Name English
ANHYDROUS CITRIC ACID COMPONENT OF CLENPIQ
Brand Name English
CITRIC ACID,ANHYDROUS [VANDF]
Common Name English
CITRIC ACID [HSDB]
Common Name English
CITRIC ACID [MI]
Common Name English
CITRIC ACID, ANHYDROUS [WHO-IP]
Common Name English
CITRIC ACID, ANHYDROUS [USP IMPURITY]
Common Name English
CITRICUM ACIDUM [HPUS]
Common Name English
NSC-30279
Code English
CITRIC ACID [FHFI]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175980
Created by admin on Fri Dec 15 16:01:39 UTC 2023 , Edited by admin on Fri Dec 15 16:01:39 UTC 2023
NDF-RT N0000175835
Created by admin on Fri Dec 15 16:01:39 UTC 2023 , Edited by admin on Fri Dec 15 16:01:39 UTC 2023
NCI_THESAURUS C275
Created by admin on Fri Dec 15 16:01:39 UTC 2023 , Edited by admin on Fri Dec 15 16:01:39 UTC 2023
NDF-RT N0000175833
Created by admin on Fri Dec 15 16:01:39 UTC 2023 , Edited by admin on Fri Dec 15 16:01:39 UTC 2023
Code System Code Type Description
RXCUI
221946
Created by admin on Fri Dec 15 16:01:39 UTC 2023 , Edited by admin on Fri Dec 15 16:01:39 UTC 2023
PRIMARY RxNorm
CAS
77-92-9
Created by admin on Fri Dec 15 16:01:39 UTC 2023 , Edited by admin on Fri Dec 15 16:01:39 UTC 2023
PRIMARY
JECFA MONOGRAPH
38
Created by admin on Fri Dec 15 16:01:39 UTC 2023 , Edited by admin on Fri Dec 15 16:01:39 UTC 2023
PRIMARY
NSC
30279
Created by admin on Fri Dec 15 16:01:39 UTC 2023 , Edited by admin on Fri Dec 15 16:01:39 UTC 2023
PRIMARY
NDF-RT
N0000008556
Created by admin on Fri Dec 15 16:01:39 UTC 2023 , Edited by admin on Fri Dec 15 16:01:39 UTC 2023
PRIMARY Decreased Coagulation Factor Activity [PE]
ECHA (EC/EINECS)
201-069-1
Created by admin on Fri Dec 15 16:01:39 UTC 2023 , Edited by admin on Fri Dec 15 16:01:39 UTC 2023
PRIMARY
MERCK INDEX
m3595
Created by admin on Fri Dec 15 16:01:39 UTC 2023 , Edited by admin on Fri Dec 15 16:01:39 UTC 2023
PRIMARY Merck Index
FDA UNII
XF417D3PSL
Created by admin on Fri Dec 15 16:01:39 UTC 2023 , Edited by admin on Fri Dec 15 16:01:39 UTC 2023
PRIMARY
DAILYMED
XF417D3PSL
Created by admin on Fri Dec 15 16:01:39 UTC 2023 , Edited by admin on Fri Dec 15 16:01:39 UTC 2023
PRIMARY
NSC
112226
Created by admin on Fri Dec 15 16:01:39 UTC 2023 , Edited by admin on Fri Dec 15 16:01:39 UTC 2023
PRIMARY
NCI_THESAURUS
C80088
Created by admin on Fri Dec 15 16:01:39 UTC 2023 , Edited by admin on Fri Dec 15 16:01:39 UTC 2023
PRIMARY
PUBCHEM
311
Created by admin on Fri Dec 15 16:01:39 UTC 2023 , Edited by admin on Fri Dec 15 16:01:39 UTC 2023
PRIMARY
CHEBI
30769
Created by admin on Fri Dec 15 16:01:39 UTC 2023 , Edited by admin on Fri Dec 15 16:01:39 UTC 2023
PRIMARY
EVMPD
SUB29050
Created by admin on Fri Dec 15 16:01:39 UTC 2023 , Edited by admin on Fri Dec 15 16:01:39 UTC 2023
PRIMARY
NSC
626579
Created by admin on Fri Dec 15 16:01:39 UTC 2023 , Edited by admin on Fri Dec 15 16:01:39 UTC 2023
PRIMARY
SMS_ID
100000093142
Created by admin on Fri Dec 15 16:01:39 UTC 2023 , Edited by admin on Fri Dec 15 16:01:39 UTC 2023
PRIMARY
DRUG CENTRAL
4473
Created by admin on Fri Dec 15 16:01:39 UTC 2023 , Edited by admin on Fri Dec 15 16:01:39 UTC 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
ANHYDROUS CITRIC ACID
Created by admin on Fri Dec 15 16:01:39 UTC 2023 , Edited by admin on Fri Dec 15 16:01:39 UTC 2023
PRIMARY Description: Colourless crystals or a white, crystalline powder; odourless or practically odourless.Solubility: Very soluble in water; freely soluble in ethanol (~750 g/l) TS; sparingly soluble in ether R.Category: Acidifying agent; buffer component.Storage: Citric acid should be kept in a well-closed container.Labelling: The designation on the container of Citric acid should state whether it is the monohydrate or the anhydrous form.Additional information. Citric acid monohydrate effloresces in dry air.
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
PARENT -> CONSTITUENT ALWAYS PRESENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
PARENT -> CONSTITUENT ALWAYS PRESENT
USP
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
PARENT -> CONSTITUENT ALWAYS PRESENT
USP
SALT/SOLVATE -> PARENT
SOLVATE->ANHYDROUS
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
PARENT -> METABOLITE INACTIVE
Unit: percent of dose; Amount combined with "Fumaric Acid"
IN-VIVO
PLASMA
Related Record Type Details
IMPURITY -> PARENT
ASSAY (COLORIMETRIC)
USP
Related Record Type Details
ACTIVE MOIETY